Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

takeda manufacturing ag - human immunoglobulin g - solution - 5 %

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

takeda manufacturing ag - human immunoglobulin g - solution - 5 %

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

takeda manufacturing ag - human immunoglobulin g - solution - 5 %

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

takeda manufacturing ag - human immunoglobulin g - solution - 5 %

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

takeda manufacturing ag - anti-d (rh0) immunoglobulin - solution - 1250 iu/ml

Israel - English - Ministry of Health

takeda israel ltd - immunoglobulins, normal human - solution for infusion - immunoglobulins, normal human 100 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - ivig can be used in all age ranges, unless otherwise specified below.replacement therapy in:primary immunodeficiency syndromes with impaired antibody production.hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed.hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation.children and adolescents (age 0-18) with congenital aids and recurrent bacterial infections.hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (hsct).immunomodulationprimary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count.guillain barré syndrome.kawasaki disease.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

takeda malaysia sdn bhd - factor viii bypassing fraction -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

takeda malaysia sdn bhd - factor viii bypassing fraction -

Israel - English - Ministry of Health

takeda israel ltd - brentuximab vedotin - powder for concentrate for solution for infusion - brentuximab vedotin 50 mg/vial - brentuximab vedotin - adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl): 1. following autologous stem cell transplant (asct) or 2. following at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. adcetris is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following asct. adcetris is indicated for the treatment of adult patients with cd30+ cutaneous t-cell lymphoma (ctcl) after at least 1 prior systemic therapy . adcetris is indicated for the treatment of adult patients with previously untreated stage iii or iv classical hodgkin lymphoma (chl), in combination with doxorubicin, vinblastine, and dacarbazine.adcetris is indicated for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl) or other cd30-expressing peripheral t-cell lymphomas (ptcl), including angioimmunoblastic t-cell lymphoma and ptcl not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

takeda manufacturing austria ag. - agua inyectable - agua inyectable....10 o 20 ml / actividad de desvÍo del inhibidor de factor viii....500 u